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Abstract In March 2014 the European Society of Radiology
(ESR) established a dedicated working group (ESR WG on
Imaging Biobanks) aimed at monitoring the existing imaging
biobanks in Europe, promoting the federation of imaging
biobanks and communication of their findings in a white pa-
per. The WG provided the following statements: (1) Imaging
biobanks can be defined as “organised databases of medical
images and associated imaging biomarkers (radiology and
beyond) shared among multiple researchers, and linked to
other biorepositories”. (2) The immediate purpose of imaging
biobanks should be to allow the generation of imaging bio-
markers for use in research studies and to support biological
validation of existing and novel imaging biomarkers. (3) A
long-term scope of imaging biobanks should be the creation
of a network/federation of such repositories integrated with
the already-existing biobanking network. The aim of the
WG was to investigate the existence, consistency, geographi-
cal distribution and type of imaging biobanks in Europe. A
survey among ESR members resulted in the identification of
27 imaging biobanks, mostly disease-oriented and designed
for research and clinical reference. In 80 % access to imaging
biobanks is restricted.
Key points
• Imaging biobanks are “shared databases of imaging bio-
markers, linked to biorepositories”.
• Exploitation of traditional and imaging biobanks is mean-
ingful for “personalised medicine”.
• A European imaging biobank network would significantly
boost research in the imaging domain.
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Introduction
Biobanks are repositories for the storage and retrieval of bio-
logical samples of a large number of subjects. A major goal of
biobanks is the organised collection of biological material and
associated information to spread access among scientists re-
quiring this information [1].
The first biobank project, established in 1948, collecting
blood samples and data, was the Framingham Heart Study
(FHS), funded by the National Institute of Health-National
Heart, Lung, and Blood Institute (NIH-NHLBI) [2]. A recent
review performed by Kang et al. reported that 70 % of the
world’s biobanks are located in Europe and that the top six
countries with biobanks are the UK (n=15), USA (n=14),
Sweden (n=12), France (n=9), The Netherlands (n=8) and
Italy (n=8) [3].
Until recently, imaging data coming from sources such as
magnetic resonance imaging (MRI) or computed tomography
(CT) were not included in such biobanks. Over the past 3–
4 years, projects have been launched that plan to acquire large
repositories of image data, including the UK Biobank and the
German National Cohort [4–6].
With the rise of these efforts it is of utmost importance to
register and document all existing and new imaging biobanks
and provide a structured unified approach for storage of and
access to these data from distributed databases. The next chal-
lenge will be to reliably connect the available imaging
biobanks to tissue biobanks to explore possible imaging bio-
markers and provide access to deep phenotypes.
Due to the vast amount of data, imaging biobanks need
specific requirements, which have to be considered when
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setting up the database. Furthermore, imaging data have to be
processed to extract quantitative information, which might
evolve into a so-called “imaging biomarker” [7].
Due to the variety of image acquisition methods and se-
quences, especially inMRI, it is crucial to store detailed image
acquisition parameters along with the image data. The large
variability in the selection of imaging acquisition parameters
in MRI provides a considerable challenge in connecting data
from multiple imaging biobanks worldwide. Harmonising
data-acquisition protocols as well as standardising image pro-
cessing methods to extract reliable information will be of great
value. The need for harmonisation, validation and
standardisation of quantifiable imaging biomarkers in medical
imaging has been the motivation to establish the Quantitative
Imaging Biomarkers Alliance (QIBATM) initiative of the Ra-
diological Society of North America (RSNA) and the Euro-
pean Imaging Biomarkers Alliance (EIBALL), initiative of




In March 2014, the European Society of Radiology also
established a dedicated working group (ESR WG on Imaging
Biobanks) aimed at monitoring the existing imaging biobanks in
Europe, promoting the federation of such imaging biobanks, and
elaborated a white paper [10]. Therefore, as part of the working
group’s objectives, this article aims to explicate the ESR’s posi-
tion on the establishment and development of imaging biobanks.
Imaging biobanks: definition and rationale
Imaging biobanks are defined as organised databases of med-
ical images, and associated imaging biomarkers (radiology
and beyond), shared among multiple researchers, linked to
other biorepositories [10].
Already existing biobanks are designed to give researchers
access to large collections of patient/subject samples and data.
Biobanks group biological material of healthy subjects
(population-based) and/or patients with specific pathologies
(disease-oriented), of which the most frequent are cancer-re-
lated. Most biobanks focus only on the collection of genotype
data, but do not simultaneously come with a system to collect
related clinical or phenotype data. In particular, most biobanks
do not include or are not linked to any kind of imaging infor-
mation, neither primary images nor imaging biomarkers.
Comprehensive exploitation of biobanks that also include im-
aging (genotype and phenotype) is an important cornerstone
in diagnostics in the era of “personalised medicine” [10–14].
Personalised medicine describes the intent to provide indi-
vidual patients with state-of-the-art diagnostic tests, tailored
interventions and specific treatments, whenever clinically in-
dicated. Personalised medicine proposes the adjustment/
customisation of health care from a one-size-fits-all approach
to a patient-specific diagnosis and treatment [15]. As such,
personalised medicine can be described as an evidence-
supported pre-selection and assignment of tests and therapy
selections to patients in need. Quantitative medical imaging,
potentially resulting in the discovery of imaging biomarkers,
is an essential part of personalised medicine providing a priori
selection criteria and a posteriori follow-up strategies, tailored
to a given patient with a specific clinical need. Obviously,
development of such strategies will be greatly enhanced by
the availability of large data repositories [16–19].
Biobanks give researchers access to large repositories of
biomaterials for a broad spectrum of further and future analy-
sis, e.g., genetic, genomic, epigenetic, mRNA, proteomics and
transcriptomics. The large scale and the broad spectrum of
data allow the detection and validation of relevant biomarkers
for personalised medicine. Moreover, biobanking in European
networks will result in harmonisation of health, lifestyle and
other exposure data as well as the development and
implemention of harmonised definitions of diseases by in-
creased consensus on the criteria for clinical endpoints.
The classical biobanking activities are to be mirrored by a
similar network of imaging biobanks. Modern radiology and
nuclear medicine can also provide multiple imaging bio-
markers of the same patient, using quantitative data derived
from all sources of digital imaging, such as CT, MRI, PET,
SPECT, US, x-ray, etc. [20, 21]. Imaging biobanks are infra-
structures with massive storage and computing capacity.
High-performance computing resources are needed to facili-
tate image processing comparison, standardisation and valida-
tion. Integration of resources and services through a platform
that manages the information flow and image processing is a
step needed in the development of imaging biobanks.
Other types of images can also be collected from endosco-
py, microscopy, surgery, etc., also providing measurable
personalised data. All this imaging information should be con-
sidered as the phenotypic expression of a patient and can be
linked to the genotype. Such data should be available to the
research community [22, 23].
A European imaging biobanks network would significantly
boost European research in the imaging domain by stimulat-
ing the design and validation of new imaging biomarkers, as
well as improving our understanding of their biological
significance.
This requires standardisation, validation and benchmarking
of the data in imaging biobanks. This activity will further
stimulate the linking and integration of existing (national
and regional) image data repositories as well as the link be-
tween imaging biobanks and traditional biobanks.
Standards will have to be developed and implemented. In-
novative solutions that promote fair access to high-quality
data sets with regard to image-based phenotypes and imaging
biomarkers will provide support to users for its utilisation.
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Finally, the economic and ethical/legal issues for the
management of imaging biobanks have to be explored.
These will advance insights and yield benefits to enhance
collaborative research, utilise limited resources effectively
and share data, technology and expertise. Research on
image data management and analysis plays a key role in
improving the performance of protocols, software-based
analysis and further methodologies for imaging biobanks
and the development and validation of imaging bio-
markers. All these aspects will surely foster high-level
multicenter collaboration.
Imaging informatics of imaging biobanks
An imaging biobank is a data repository supporting the
gathering, querying and dissemination of imaging data for
primary or secondary use in research, education and train-
ing. It comprises a repository of images and a database to
support indexing based on the organ, modality or pathol-
ogy, etc.
An imaging biobank may be used for different research
purposes, for example, defining and validating new imag-
ing biomarkers for diagnosis or prognosis, by comparing
them with existing proven (imaging) biomarkers. It may
also be used to identify the genetic origin of a disease or
factors (including environmental factors) favouring dis-
ease development (cohort studies). The images may also
be used to build high-quality anatomical templates, tai-
lored to specific populations, e.g., young subjects between
15 and 20 years or patients with Parkinson's disease above
65 years.
General requirements with respect to the data collec-
tion are therefore a database facilitating storage of image
data and metadata, storage of derived image-based mea-
surements and storage of associated non-imaging data,
taking into account the need to deal with longitudinal data
and to cope with multiple file formats (DICOM, of
course, but also formats used in research and post-
processing settings such as NifTI) [24]. With respect to
security, functional and technical requirements should be
defined with respect to data transformation (including de-
identification and encryption), infrastructure (e.g., user
identity management, audit log) and data access and
movement (including authorisation and transmission pro-
tection) [25]. International collaboration will require the
advance of both technological and organisational matters
(incorporation, procedures, protocols, data sharing, boards
and access criteria). This new environment can be consid-
ered as a framework on top of a set of computing and
data-intensive infrastructures that will provide researchers
with tools, protocols, data and expertise to improve med-
ical imaging research and patient health care.
Three main scenarios currently exist in terms of setup:
1. imaging biobanks of clinical research data
2. imaging biobanks with disease-specific data (not neces-
sarily connected to a precise clinical research question)
3. imaging biobanks with general population data
First scenario In this scenario, imaging biobanks are en-
visaged as infrastructure to archive, share
and disseminate (for secondary use) image
data that were originally used in the context
of clinical research projects, such as clini-
cal trials. In this scenario, the images may
have undergone some image processing in
order to extract one or more imaging bio-
markers relevant to the scientific question
that motivated the study. It is natural to
store such biomarkers as well as related
provenance metadata in the imaging
biobank database.
Second scenario In this scenario, imaging biobanks are en-
visaged as resources to receive, archive,
share and disseminate images in specific
clinical domains, e.g., Alzheimer’s disease
or multiple sclerosis. Such systems aim at
collecting the clinical images of patients
with a given pathology on a broad scale
(e.g., national scale). They usually address
common specific image acquisition proto-
cols and ensure quality control at the time
of image importation to ensure optimal im-
age use. These imaging biobanks can also
be based on a regional or national screen-
ing initiative collecting image data of a
group of persons with specific characteris-
tics such as habits, previous disease or a
genetic profile. Breast cancer, lung cancer
and colon cancer screenings are examples
of image-based screening with subsequent
storage of images in an imaging biobank.
Third scenario In this scenario, imaging biobanks are com-
posed of data collections obtained from the
general population without a specific re-
search goal or disease-oriented approach.
Longitudinal data are collected over a long
period of time with as much data collected
of as many subjects as possible. Research
projects may gain paid access to this data
upon request for a specific research ques-
tion. The technical setup of this scenario is
similar to the second scenario, but the data
collection is not performed for clinical pur-
poses and will in many cases be acquired
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by entities established especially for the da-
ta collection of the population study.
Services provided by imaging biobanks
(1) Management of image collections: This involves sev-
eral aspects: (a) negotiating the conditions of image ac-
ceptance and conservation: duration of conservation, for-
mats, image quality, sharing with owners, sharing with
other parties, general and specific (i.e., collection-depen-
dent) metadata, ability to link to external data (clinical
information, biological information, biological speci-
men); (b) defining metadata associated with a new image
collection; (c) applying workflow when a new image is
added to a collection (receiving images from a source
and assessing image quality, recording information about
data acquisition and acquisition devices, assessing prop-
er data selection according to the specific research pro-
ject, recording additional information besides the images
such as measurements, functional data).
(2) Supporting image collections’ consultation: This in-
cludes sending study requests to a review committee that
determines the scientific merit and checks for similar
requests that were previously granted. If approved, the
committee sets up access rights at the desired level to the
selected subset of the data and supports query/retrieval
processes, i.e., processing queries from external parties,
verifying access rights, querying the database, providing
references of images and related metadata, and
downloading images.
(3) Relating image cases to external data (data,
specimen): This involves: (a) receiving notifications from
external parties, (b) cross-referencing identifiable informa-
tion to connect the two databases and determine subjects for
which this is feasible and reliable enough, and (c) updating
the database with the references of external data.
(4) Production of imaging biomarkers: This service re-
quires the prior definition of a process to validate the
imaging biomarker to guarantee to the requesting party
that the measurements performed are accurate.
Standardisation and registration of the process should
also be part of this. The biomarkers’ calculation service
includes: (a) applying the relevant image-processing
workflow, (b) recording the calculated values in the da-
tabase as well as (c) the detailed provenance data (by
whom, how and when such data were obtained).
Federated access to imaging biobanks
A key feature is to provide end-users with large federated
systems (e.g., through a web portal or a set of web services),
facilitating data query from multiple imaging biobanks. This
avoids users querying all the imaging biobanks successively
that they believe might contain the kind of data they are
looking for. Providing such service involves:
(1) setting up a catalogue of image collections provided by
multiple imaging biobanks;
(2) striving towards a “federated data model” for databases
querying (e.g., using common data schemas, standard
nomenclatures, reference to common ontologies);
(3) receiving queries from external parties;
(4) querying the distributed databases according to the “fed-
erated data model”;
(5) providing image metadata matching the query, including
references to image data. These federated systems will im-
prove health care through studies of quality control, such as
image quality and radiation dose, technical and protocol
comparisons, follow-up assessment of clinical guidelines,
fast translation of research findings into image-guided
management, assessment of image biomarker prognostic
factors and early assessment of treatment response.
Clinical focus
Imaging biobanks should be focussed on collecting data from
healthy subjects or—disease-oriented—from patients (onco-
logic imaging, rare diseases, other). In the case of healthy
subjects (as in the UK Biobank), it should be considered
how these data can be collected to ensure participant safety
and identity protection. In principle, the imaging acquisition
should minimise or avoid the use of ionising radiation with
greater dependence on US and MRI in healthy subjects. In
contrast, disease-related IB can also be collected by x-ray
and (ultra) low-dose CT, represented by data derived from
screening programmes for breas t cancer (x- ray
mammography) and colon and lung cancer (CTcolonography
and low-dose lung CT) [26–30]. Furthermore, developments
in CT imaging with ultra-low-dose acquisitions could open
the possibility of CT imaging in population screening for sub-
jects above a certain age.
Oncologic imaging seems to be the easier setting for the
collection of imaging biomarkers from multiple imaging mo-
dalities. Oncology patients routinely undergo multiple imag-
ing studies for staging and follow-up of the disease to evaluate
the TNM and the treatment response. The same patients un-
dergo multiple laboratory tests, pathologic specimen analysis
(which provides further imaging data), genetic sequencing,
etc. In this setting it seems highly relevant to link imaging
biomarkers derived from clinical investigation with those col-
lected by traditional biobanking [31].
Clinical researchwill benefit from the increased production of
scientific researchers' contributions from the field of radiology.
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Economics, standards, security, legal issues
Economic
The creation and realisation of biobanks is a very expensive
process because of the involvement of a large number of partic-
ipants, e.g., the UK Biobank with about 500,000 participants or
the nationwide biobank in Iceland. Imaging procedures as part of
prospective cohort studies will contribute to the overall costs in a
relevant portion, especially if MR imaging is necessary because
of the research focus and radiation exposure, contrast media or
medication with other modalities (e.g., cardiac CT).
In large studies, dedicated imaging centres have been
established or are in planning. Based on the example of the
UK, it has been shown that the costs per participant would be
approximately €500; however this would end up at about
€50 M for the imaging part based on the assumption of 100,
000 participants [32].
Standards
Standards are relevant for different levels, e.g., legal regula-
tion, organisational issues for the institution, standard operat-
ing procedures for handling of data and samples, but also for
the syntax and semantic (ontologies) representation in infor-
mation systems.
In the context of medical imaging, there are three major
topics:
Reporting: there is a common trend to structured
reporting worldwide [33]. Automated evaluation of infor-
mation in databanks would work best with standardised
documentation of findings and measurements. There are
relatively mature solutions providing the platform for
such efforts. The Integrating the Healthcare Enterprise
(IHE) profile, “Managing Radiology Report Templates”,
describes the use of appropriate templates. Recommen-
dations for workflows and implementations are available,
while first implementations are under evaluation [33].
Semantic Interoperability: Imaging procedures for imag-
ing biobanks will very often rely on quantitative imaging
biomarker data, to be exchanged between systems. Suitable
models should therefore be defined to describe them in an
explicit and consistent way, ideally using semantic models
such as ontologies (e.g., SNOMED, RadLex, ICD).
Imaging and communication formats: due to the world-
wide acceptance of DICOM there are minor issues in the
topic of imaging formats. DICOM has ongoing revised
and new requirements, e.g., new imaging techniques or
ontologies will be included into the standard. Workflows
and communication across institutions are almost cov-
ered by IHE profiles. Based on the IHE Cross-
Enterprise-Communication concept (IHE-XDS family),
which is the core of many regional and national eHealth
concepts, there is already a logical approach for
connecting imaging centres with imaging biobanks. The-
se IHE-XDS concepts would allow decentral storage of
primary data, but also the aggregation of data, and also
communication across different imaging biobank do-
mains (www.ihe.net). Actually, there is a missing link
between the imaging world and the information about
biobanks. The description of requirements and
workflows should be followed by the development of
an appropriate IHE profile for these use cases [34, 35].
Security and legal issues
Security and legal issues are two of themost challenging tasks in
building large research databases in general. This is due to the
requirements for the probable long-term aggregation of medical
data from different sources linked with personal information on
one side and the request for patient privacy and security aspects
on the other. Such databases might contain personal data and
information, and also digitised collections of specimens such as
tissues or blood, genomic and imaging data.
Many of such research-oriented databases are built as leg-
acy systems with proprietary regulations, regulated by differ-
ent levels of privacy rules, for example [36, 37].
There are some examples of concepts for the legal frame-
works for biobanking; one of these is from the German
“Telematics Platform of Medical Research Network” (TMF)
[38]. One of the relevant requirements is a solution for inter-
disciplinary and active collaboration between different institu-
tions, for which the property rights and privacy of the “do-
nors” (information data and/or biological material from vol-
unteers and patients) have to be protected, even for scientific
and also possible commercial use by third parties.
Therefore different legal requirements have to be consid-
ered [39]:
& Legal status of the institution organising and maintaining
the databank.
& Property rights of samples and information, will often
require explicit transfer of rights by the donor.
& Relevance of medico-legal and professional regulations,
e.g., the acquisition of samples is usually a medical act,
which requires interaction with a physician, even in a re-
search setting. Another topic is a regulation about the
communication on new findings while in research or data
analysis, which might impact the health of the donor.
& Continuity of databanks in case of ending projects or
insolvence of the institution;
& Secure transfer of samples or information and secure
storage;
& Confiscation protection and research secrecy.
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The complexity in building large databanks for internation-
al collaboration may increase in case of different national reg-
ulations. The actual development at the European level with
the preparation of a General Data Protection Regulation
(COM (2012) 0011) will also be relevant for the future of
imaging biobanks [40].
There is an interest in unified worldwide legislation regard-
ing privacy issues and ownership, also to require mandatory
registration of biobanks.
Imaging biobanks in Europe: results of the ESR
survey
One of the aims of the working group was to investigate the
existence, consistency, geographical distribution and type of
imaging biobanks in Europe.
A survey was carried out, using a free online poll service
(www.surveymonkey.com), inviting heads of radiology
departments across Europe to answer the following nine
questions: purpose of the biobank, types of cases, number of
cases, kind of imaging data, presence of follow-up image ex-
aminations, already existing publications on the image
biobank, accessibility of the image biobank (open, restricted
to user), imaging data supported and image format.
The results of the questionnaire are summarised in Table 1.
Twenty-seven responses were received from Austria, Fin-
land, France, Germany, Kazakhstan, Italy, Russia, Slovenia,
Spain, Sweden, Switzerland, The Netherlands, Turkey and the
UK.
Most biobanks are for research and clinical reference and
are disease-oriented (oncologic and cardiovascular type of
cases); the number of cases included is extremely variable,
but mostly less than 1000, and most biobanks contain CT
and MR images.
Of note, the accessibility of the biobanks is in the vast
majority (80 %) restricted to registered users involved in
predefined projects or personnel of the local department/
hospital.
Conclusion
Medical imaging biobanks are virtual biobanks recently
emerging for advancing the study of rare, cardiovascular, on-
cologic and neurological diseases, the identification of early
biomarkers and surrogates, and the development of population
studies. These biobanks will evaluate the impact of new quan-
titative biomarkers in early disease diagnosis, disease pheno-
typing, disease grading, targeting therapies and evaluation of
disease response to treatment.
Such imaging biobanks are currently at an early stage of
development and dissemination within Europe. The survey
carried out among heads of radiology departments across Eu-
rope proved the existence and operation of some disease-
oriented patient- or healthy population-based image data-
bases. Most of them were developed within institutional
Table 1 Results of the ESR survey on imaging biobanks
Purpose of the biobank Number
(percentage)
Research 14 (82.4)
Clinical reference 12 (70.6)
e-learning 9 (52.9)
Other 1 (5.9)
Types of cases available
Oncologic 13 (76.5)
Cardiovascular 8 (47.1)
Healthy volunteers 7 (41.2)
Rare diseases 6 (35.3)
Other 6 (35.3)
Number of cases available




More than 2000 5 (29.4)
Kind of imaging data available
Computed tomography 14 (82.4)
Magnetic resonance 15 (88.2)
Hybrid imaging 5 (29.4)
Ultrasound 9 (52.9)
Other 5 (29.4)
Availability of follow-up image examinations
Not available 5 (29.4)
Available 12 (70.6)
Availability of publications based in the image biobank
Not available 12 (70.6)
Available 5 (29.4)
Accessibility to the biobank
Fully open on the Internet 1 (6.3)
Open to any registered user (free registration) 2 (12.5)
Restricted to users involved in predefined projects 5 (31.3)




Strictly limited to acquired images 5 (31.3)
Also contains processed images (segmentation,
registration, etc.)
8 (50.0)
Also contains imaging biomarkers 3 (18.8)
Image formats
Strictly limited to DICOM 13 (81.3)
DICOM and other common formats used in
research (such as NIFTI, Analyze)
1 (6.3)
Also contains imaging biomarkers 2 (12.5)
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projects and are not freely accessible. The working group
elaborated the rationale, definition, technical, clinical, eco-
nomics, management, legal and ethical issues related to the
setup, development, federation and maintenance of imaging
biobanks. As the imaging biobanks are focussing on the phe-
notype expression, there is an unmet need to link the informa-
tion to other biomarkers from other sources of information,
especially all biobanks. Therefore the working group en-
dorsed the integration of imaging biobanks with already tra-
ditional biobanks (genomic, tissue and other type of “omics”),
since the joint exploitation of both biobanks is an important
cornerstone for diagnosis and targeted therapies in the era of
personalised medicine.
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